Login to Your Account

Other News To Note

Wednesday, May 22, 2013

• Helsinn Healthcare SA, of Lugano, Switzerland, and Vifor Pharma, of Villars-sur-Glane, Switzerland, signed an exclusive license and distribution agreement for netupitant-palonosetron fixed-dose combination, an investigational Helsinn product for chemotherapy-induced nausea and vomiting, giving rights to Vifor to distribute the product in Switzerland, France, Spain, Portugal, the Netherlands, Belgium and Luxembourg.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription